M&A / Deals

Coultreon banks $125M to support testing of former Galapagos immune drug

BioPharma Dive

Backed by Novo Holdings, Regeneron s venture arm and several others, the biotech believes an oral drug licensed from Galapagos might hold potential treating many immunological diseases.

Immunology & Inflammation

Read full story

pharminent April 28, 2026 (Last updated: April 29, 2026)

BioPharma Dive

Backed by Novo Holdings, Regeneron s venture arm and several others, the biotech believes an oral drug licensed from Galapagos might hold potential treating many immunological diseases.

Immunology & Inflammation

Read full story

Related Stories

Eli Lilly to buy trio of vaccine developers in $3.8bn outlay

Gilead inks $140M API supply deal, tightening ties to Korean manufacturer

GBL joins CVC in 10.7bn takeover bid for Recordati

You May Have Missed

Eli Lilly to buy trio of vaccine developers in $3.8bn outlay

Arthrosi drug trial in gout delivers for new owner Sobi

Lilly’s Verve gambit pays off as base editor cuts cholesterol in early study

Pierre Fabre’s Braftovi gains CHMP positive opinion for mCRC